Potential Options to Treat Hypertriglyceridaemia

Authors: Viljoen, Adie; Wierzbicki, Anthony S.

Source: Current Drug Targets, Volume 10, Number 4, April 2009 , pp. 356-362(7)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

OR

Price: $63.10 plus tax (Refund Policy)

Abstract:

Hypertriglyceridaemia is associated with insulin resistance, hypertension, obesity and diabetes. The management of hypertriglyceridaemia and atherogenic dyslipidaemias increasingly involves the use of several drugs for different aspects of the metabolic syndrome. This review highlights the agents for treatment of blood pressure, weight and blood pressure that reduce triglycerides as a number of drugs used to treat these co-morbidities also lower triglycerides as additional effects beyond their primary actions. Lipid-lowering drugs particularly fibrates and niacin and to a lesser degree statins and omega-3 fatty acids reduce plasma triglyceride levels. Additional reductions can be gained from the appropriate choice of therapies for co-morbid condition as the optimal combinations may offer benefits in improving cardiovascular risk as well as compliance.

Keywords: Triglyceride; insulin resistance; metabolic syndrome; drug; hypoglycaemic agent; anti-hypertensive therapy; lipidlowering drug

Document Type: Research article

Publication date: 2009-04-01

More about this publication?
  • Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page